Literature DB >> 21148760

Apoptosis in severe, compensated pressure overload predominates in nonmyocytes and is related to the hypertrophy but not function.

Ricardo J Gelpi1, Misun Park, Shumin Gao, Sunil Dhar, Dorothy E Vatner, Stephen F Vatner.   

Abstract

It is widely held that myocyte apoptosis in left ventricular hypertrophy (LVH) contributes to left ventricle (LV) dysfunction and heart failure. The main goal of this investigation was to determine if there is a statistical relationship among LV hypertrophy, apoptosis and LV function, and importantly whether the apoptosis occurs in myocytes or nonmyocytes in the heart. We used both rat and canine models of severe LVH induced by chronic thoracic aortic banding with resultant LV-aortic pressure gradients 145-155 mmHg and increases in LV/body weight of 58 and 70%. These models also provided the ability to examine transmural apoptosis in LVH. In both models, the overwhelming majority (88%) of apoptotic cells were nonmyocytes. The regressions for apoptosis vs. LVH were stronger for nonmyocytes than myocytes and also stronger in the subendocardium than the subepicardium. Importantly, LV systolic and diastolic wall stresses were normal, indicating that the apoptosis could not be attributed to LV stretch or heart failure. In addition, there was no relationship between the extent of apoptosis and LV ejection fraction, which actually increased (P < 0.05), in the face of elevated LV systolic pressure, indicating that greater apoptosis did not result in a decrease in LV function. Thus, in response to chronic, severe pressure overload, LVH in the absence of LV dilation, and elevated LV wall stress, apoptosis occurred predominantly in nonmyocytes in the myocardial interstitium, more in the subendocardium than the subepicardium. The extent of apoptosis was linearly related to the amount of LV hypertrophy, but not to LV function.

Entities:  

Mesh:

Year:  2010        PMID: 21148760      PMCID: PMC3302193          DOI: 10.1152/ajpheart.00998.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  18 in total

1.  Telomerase expression and activity are coupled with myocyte proliferation and preservation of telomeric length in the failing heart.

Authors:  A Leri; L Barlucchi; F Limana; A Deptala; Z Darzynkiewicz; T H Hintze; J Kajstura; B Nadal-Ginard; P Anversa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

2.  Activation of apoptotic caspase cascade during the transition to pressure overload-induced heart failure.

Authors:  Narain Moorjani; Manzoor Ahmad; Pedro Catarino; Robin Brittin; Danyah Trabzuni; Futwan Al-Mohanna; Navneet Narula; Jagat Narula; Stephen Westaby
Journal:  J Am Coll Cardiol       Date:  2006-09-12       Impact factor: 24.094

Review 3.  Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?

Authors:  Bodh I Jugdutt
Journal:  Circulation       Date:  2003-09-16       Impact factor: 29.690

4.  ANG II type 1A receptor signaling causes unfavorable scar dynamics in the postinfarct heart.

Authors:  Yiwen Li; Genzou Takemura; Hideshi Okada; Shusaku Miyata; Hiromitsu Kanamori; Rumi Maruyama; Masayasu Esaki; Longhu Li; Atsushi Ogino; Takamasa Ohno; Takehito Kondo; Munehiro Nakagawa; Shinya Minatoguchi; Takako Fujiwara; Hisayoshi Fujiwara
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-10-06       Impact factor: 4.733

5.  Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat.

Authors:  G Condorelli; C Morisco; G Stassi; A Notte; F Farina; G Sgaramella; A de Rienzo; R Roncarati; B Trimarco; G Lembo
Journal:  Circulation       Date:  1999-06-15       Impact factor: 29.690

Review 6.  Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure.

Authors:  R R Ruffolo; G Z Feuerstein
Journal:  J Cardiovasc Pharmacol       Date:  1998       Impact factor: 3.105

7.  Contribution of non-cardiomyocyte apoptosis to cardiac remodelling that occurs in the transition from compensated hypertrophy to heart failure in spontaneously hypertensive rats.

Authors:  S Ikeda; M Hamada; K Hiwada
Journal:  Clin Sci (Lond)       Date:  1999-08       Impact factor: 6.124

8.  Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing.

Authors:  J Zhao; J Li; W Li; Y Li; H Shan; Y Gong; B Yang
Journal:  Br J Pharmacol       Date:  2010-01-15       Impact factor: 8.739

9.  Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression.

Authors:  David Engel; Ronald Peshock; Robert C Armstong; Natarajan Sivasubramanian; Douglas L Mann
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-09       Impact factor: 4.733

10.  A mechanistic role for cardiac myocyte apoptosis in heart failure.

Authors:  Detlef Wencker; Madhulika Chandra; Khanh Nguyen; Wenfeng Miao; Stavros Garantziotis; Stephen M Factor; Jamshid Shirani; Robert C Armstrong; Richard N Kitsis
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

View more
  9 in total

1.  Innervating sympathetic neurons regulate heart size and the timing of cardiomyocyte cell cycle withdrawal.

Authors:  R E Kreipke; S J Birren
Journal:  J Physiol       Date:  2015-11-04       Impact factor: 5.182

Review 2.  Large animal models of heart failure with preserved ejection fraction.

Authors:  Chihiro Miyagi; Takuma Miyamoto; Taiyo Kuroda; Jamshid H Karimov; Randall C Starling; Kiyotaka Fukamachi
Journal:  Heart Fail Rev       Date:  2021-11-09       Impact factor: 4.214

3.  A New Therapeutic Alternative for the Treatment of Pulmonary Hypertension?

Authors:  Ricardo J Gelpi
Journal:  Arq Bras Cardiol       Date:  2021-12       Impact factor: 2.667

4.  Rats are protected from the stress of chronic pressure overload compared with mice.

Authors:  Koichi Nishimura; Marko Oydanich; Jie Zhang; Denis Babici; Diego Fraidenraich; Dorothy E Vatner; Stephen F Vatner
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-03-25       Impact factor: 3.619

5.  Disruption of type 5 adenylyl cyclase prevents β-adrenergic receptor cardiomyopathy: a novel approach to β-adrenergic receptor blockade.

Authors:  Lin Yan; Stephen F Vatner; Dorothy E Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-09-05       Impact factor: 4.733

6.  A combined linkage, microarray and exome analysis suggests MAP3K11 as a candidate gene for left ventricular hypertrophy.

Authors:  Claudia Tamar Silva; Irina V Zorkoltseva; Maartje N Niemeijer; Marten E van den Berg; Najaf Amin; Ayşe Demirkan; Elisa van Leeuwen; Adriana I Iglesias; Laura B Piñeros-Hernández; Carlos M Restrepo; Jan A Kors; Anatoly V Kirichenko; Rob Willemsen; Ben A Oostra; Bruno H Stricker; André G Uitterlinden; Tatiana I Axenovich; Cornelia M van Duijn; Aaron Isaacs
Journal:  BMC Med Genomics       Date:  2018-03-05       Impact factor: 3.063

7.  Truncations of the titin Z-disc predispose to a heart failure with preserved ejection phenotype in the context of pressure overload.

Authors:  Lei Ye; Liping Su; Chenxu Wang; Szejie Loo; Guizhen Tee; Shihua Tan; Sandar Win Khin; Shijie Ko; Boyang Su; Stuart A Cook
Journal:  PLoS One       Date:  2018-07-31       Impact factor: 3.240

8.  Therapeutic knockdown of miR-320 improves deteriorated cardiac function in a pre-clinical model of non-ischemic diabetic heart disease.

Authors:  Nilanjan Ghosh; Sonya Fenton; Isabelle van Hout; Gregory T Jones; Sean Coffey; Michael J A Williams; Ramanen Sugunesegran; Dominic Parry; Philip Davis; Daryl O Schwenke; Anirudha Chatterjee; Rajesh Katare
Journal:  Mol Ther Nucleic Acids       Date:  2022-07-13       Impact factor: 10.183

Review 9.  Animal models of heart failure with preserved ejection fraction.

Authors:  G Conceição; I Heinonen; A P Lourenço; D J Duncker; I Falcão-Pires
Journal:  Neth Heart J       Date:  2016-04       Impact factor: 2.380

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.